新一代治疗糖尿病药物对阿尔茨海默病的干预机制及进展  

Mechanism and progress of new drugs for treatment of diabetes in intervention of Alzheimer's disease

作　　者：张翼鸿[1] 杨艳[1] 马峻峰[1] 于淼[1] 李佳乐[1] 

机构地区：[1]黑龙江省医院南岗院区内分泌科,哈尔滨150001

出　　处：《中华老年多器官疾病杂志》2017年第11期863-867,共5页Chinese Journal of Multiple Organ Diseases in the Elderly

基　　金：黑龙江省青年科学基金(QC2014C114)~~

摘　　要：2型糖尿病(T2DM)与阿尔茨海默病(AD)在病因及病理生理方面具有相似性,近年研究表明胰高血糖素样肽1(GLP-1)、二肽基肽酶4(DPP-4)抑制剂、钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂等新型降糖药有中枢作用,为此学者们提出了治疗AD的新策略,即应用控制T2DM的新型药物干预AD。本文综述了AD病理生理特点,AD和T2DM的相关性以及GLP-1、DPP4抑制剂、SGLT2抑制剂治疗AD的相关研究进展。Type 2 diabetes mellitus（T2DM）is proven to have some similarities in etiology and pathophysiology with Alzheimer＇s disease（AD）.In recent years, evidence also has suggested that some new drugs for diabetes, such as glucagon-like peptide 1 （GLP-1）,dipeptidyl peptidase 4（DPP-4）inhibitor, and sodium-glucose co-transporter 2（SGLT2）inhibitor, have some effects on the central nervous system.These findings provide new strategy for AD treatment,that is,using these diabetes drugs for intervention of AD.In this paper,we reviewed the pathophysiological characteristics of AD,the correlation between AD and T2DM,and the applica-tion of GLP-1,DPP-4 inhibitor and SGLT2 inhibitor in the intervention of AD.

关 键 词：2型糖尿病 阿尔茨海默病 血糖素样肽1 二肽基肽酶4抑制剂 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R979[医药卫生—药品] R741[医药卫生—药学]